Key result
Specific ELISA method validates plasma TAFI Ag levels to assess stroke evolution and thrombolytic response.
Why the study?
Plasma TAFI antigen levels show great inter-individual variability in healthy populations, and it is unclear if this is due to physiologic or methodological factors.
The study validates an ELISA method for measuring TAFI Ag levels to better interpret results in patients with vascular diseases, including acute ischemic stroke.
Validated TAFI ELISA supports consistent measurement in stroke research; leaves open clinical utility pending outcome-linked validation.
Thrombin activable fibrinolysis inhibitor antigen levels (TAFI Ag ) exhibit a great inter-individual variability in healthy populations. Our aim is to determine whether variability is due to physiologic variations depending on genetic control or due to validation of the method,in order to allow a better interpretation of the results inpatients with vascular diseases. With this purpose, we performed a strategy validation of specific ELISA method, Zymutest TAFI Ag Hyphen Biomed, base don a commercial monoclonal antibody. After methodology validation we have recently determined plasma TAFI Ag levels in several groups of diseases such as septic patients, menopause and cerebrovascular diseases. TAFI was finally determined in acute ischemic stroke to know its relationship with stroke evolution and response to thrombolytic treatments.
No takes yet. Share an insight, caveat, or question.
Monasterio et al. (2003) studied Healthy subjects and patients with vascular diseases. Plasma TAFI Ag levels was evaluated on TAFI Ag levels and relationship with stroke evolution and response to thrombolytic treatments. A specific ELISA method for measuring plasma TAFI Ag levels was validated to assess its relationship with stroke evolution and response to thrombolytic treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: